Citadel Advisors
PDSB icon

Citadel Advisors’s PDS Biotechnology PDSB Stock Holding History

Citadel Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.84K Buy
+11,300
New +$8.5K ﹤0.01% 12793
2025
Q4 		– Sell
-28,400
Closed -$28.7K – 13713
2025
Q3 		$28.7K Sell
28,400
-32,600
-53% -$38.3K ﹤0.01% 12409
2025
Q2 		$81.1K Sell
61,000
-6,900
-10% -$9.37K ﹤0.01% 11490
2025
Q1 		$80.8K Buy
67,900
+59,600
+718% +$84.8K ﹤0.01% 11750
2024
Q4 		$13.5K Buy
8,300
+7,400
+822% +$19.6K ﹤0.01% 13440
2024
Q3 		$3.44K Sell
900
-3,900
-81% -$13K ﹤0.01% 13654
2024
Q2 		$14.1K Sell
4,800
-6,100
-56% -$19.5K ﹤0.01% 12902
2024
Q1 		$43.2K Sell
10,900
-155,700
-93% -$802K ﹤0.01% 12318
2023
Q4 		$828K Buy
166,600
+33,000
+25% +$164K ﹤0.01% 7057
2023
Q3 		$675K Buy
133,600
+5,700
+4% +$31.2K ﹤0.01% 7406
2023
Q2 		$643K Sell
127,900
-56,000
-30% -$367K ﹤0.01% 7389
2023
Q1 		$1.13M Sell
183,900
-219,500
-54% -$1.8M ﹤0.01% 6503
2022
Q4 		$5.32M Buy
403,400
+47,800
+13% +$337K ﹤0.01% 3751
2022
Q3 		$1.06M Sell
355,600
-59,100
-14% -$251K ﹤0.01% 6873
2022
Q2 		$1.51M Buy
414,700
+169,600
+69% +$806K ﹤0.01% 6112
2022
Q1 		$1.52M Buy
245,100
+197,400
+414% +$1.23M ﹤0.01% 6709
2021
Q4 		$386K Sell
47,700
-11,200
-19% -$121K ﹤0.01% 10307
2021
Q3 		$878K Buy
58,900
+7,400
+14% +$92.3K ﹤0.01% 8475
2021
Q2 		$646K Buy
+51,500
New +$402K ﹤0.01% 9433
2019
Q1 		– Sell
-1,630
Closed -$10K – 9714
2018
Q4 		$10K Buy
+1,630
New +$21.6K ﹤0.01% 8926

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's PDSB Position: Q4 2025 in Review

Citadel Advisors sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 386,430 shares — an estimated $390K sold.

Citadel Advisors first reported a position in PDSB in Q1 2018 and held it in 19 quarters. The position peaked at $3.26M in Q3 2021. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Citadel Advisors reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 386,430 PDS Biotechnology shares in Q4 2025, an estimated $390K.
  • Citadel Advisors first reported a position in PDS Biotechnology in Q1 2018 and held it in 19 quarters.
  • Citadel Advisors's PDS Biotechnology position peaked at $3.26M in Q3 2021.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.